BUY Krishna Institute of Medical Sciences Limited — IDBI Capital
byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))24 Jul 2026via IDBI Capital Research Calls Telegram
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Alembic Pharma, KIMS Get Target Price Hikes After Q1, Latent View Sees Downgrade: ICICI Securities
NewsNdtv-Profit·5 Aug · yesterday
2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · same horizon·27 Jul · 1w ago
Indian Pharma Q1 FY27 Deals: సన్ ఫార్మా అద్భుతంతో **$13.9 బిలియన్** విలువ నమోదు
NewsGoogle News·23 Jul · 2w ago
सन फार्माच्या डीलमुळे भारतीय फार्मा सेक्टरमध्ये ₹13.9 बिलियनचा व्यवहार; विशेष पोर्टफोलिओवर भर
NewsGoogle News·23 Jul · 2w ago
2 advisors have active short-term BUY calls on this stock
Advisor consensus · adjacent horizon·9 Jul · 4w ago
Krishna Institute of Medical Sciences Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported total revenue of INR 1,196 Cr, a growth of 36.1% YoY
BSE · Company Update·3 Aug · 2d ago
Krishna Institute of Medical Sciences Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The results will be available on the company's website.
NSE · Press Release·3 Aug · 2d ago
Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·3 Aug · 2d ago
KIMS Shares Trade Near ₹780 Support Level
NewsGoogle News·27 Jul · 1w ago
KIMS Share Price: ₹780 च्या सपोर्ट लेव्हलवर!
NewsGoogle News·27 Jul · 1w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.